Roche Announces New Results from EMBARK Study of Elevidys in Duchenne Muscular Dystrophy
2025-01-27 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, January 27, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on January 27 (local time) regarding new results from EMBARK study of delandistrogene moxeparvovec, a gene therapy product under development (development code: SRP-9001, overseas product name: Elevidys) for Duchenne muscular dystrophy (DMD). Please refer to the link below for details of the press release: Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) https://www.roche.com/media/releases/med-cor-2025-01-27
The release as fetched from its publisher. chugai-pharm.co.jp ↗